Method for stabilizing SMG1 protein, method for screening SMG1 inhibitor, and SMG1 inhibitor

Stabilizing SMG1 protein with SMG9 in the presence of polysorbate surfactants enables efficient screening and identification of specific SMG1 inhibitors, addressing the non-specificity of existing inhibitors and enhancing kinase activity measurement.

JP7591805B2Active Publication Date: 2024-11-29PUBLIC UNIV CORP YOKOHAMA CITY UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020114180
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-01
Publication Date
2024-11-29
Estimated Expiration
2040-07-01

AI Technical Summary

Technical Problem

Existing SMG1 inhibitors are non-specific, affecting other kinases like mTOR, and there is a need for a method to stabilize SMG1 protein for efficient purification and screening of specific SMG1 inhibitors.

Method used

Stabilizing SMG1 protein by forming a complex with SMG9 in the presence of polysorbate-type nonionic surfactants, such as polyoxyethylene (20) sorbitan monolauryl ether, and using this complex to screen for SMG1 inhibitors by measuring kinase activity.

Benefits of technology

A high-throughput screening method identifies specific SMG1 inhibitors with reduced activity, providing a stable SMG1 protein complex for effective kinase activity measurement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591805000011
    Figure 0007591805000011
  • Figure 0007591805000012
    Figure 0007591805000012
  • Figure 0007591805000013
    Figure 0007591805000013
Patent Text Reader

Abstract

To provide a screening method of an SMG1 inhibitor, a method for stabilizing SMG1 protein which is used in the screening method and useful for a large-scale purification method of SMG1, and a novel SMG1 inhibitor discovered by the screening method.SOLUTION: A screening method of an SMG1 inhibitor includes: a process of bringing SMG1 protein complexed with SMG9 into contact with a compound of an SMG1 inhibitor candidate under the coexistence of polysorbate-type nonionic surfactant to measure the kinase activity of SMG1; and a process of selecting a compound in which reduction of the kinase activity of SMG1 has been recognized. A method for stabilizing the SMG1 protein includes maintaining the SMG1 protein or a protein complex including the SMG1 protein under the coexistence of polysorbate-type nonionic surfactant.SELECTED DRAWING: Figure 6
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for stabilizing an SMG1 protein, a method for screening an SMG1 inhibitor, and an SMG1 inhibitor. [Background technology]

[0002] Protein kinase SMG1 is a rate-limiting enzyme in the NMD (nonsense-mediated mRNA decay) pathway, and is attracting attention as a target protein for drugs aimed at inducing cancer immunity and improving hereditary diseases.

[0003] Suppression of NMD induces cancer immunity through the induction of expression of cancer-specific antigens derived from abnormal genes in cancer cells (Non-Patent Document 1). Suppression of NMD enhances radiation sensitivity (Non-Patent Document 2). Suppression of NMD inhibits the proliferation of cancer cells (Non-Patent Document 3). In other words, suppression of NMD is expected to have an anticancer effect. It has also been suggested that suppression of NMD may improve symptoms of rare hereditary diseases (Non-Patent Document 4). Thus, NMD has potential as a drug discovery target.

[0004] Although SMG1 inhibitors have been reported so far (Non-Patent Document 5), these SMG1 inhibitors also inhibit mTOR and are therefore not specific to SMG1. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Pastor F., Nature, volume 465, pages 227-230 (13 May 2010) [Non-Patent Document 2] Gubanova E., Clinical Cancer Research, Volume 18, Issue 5, pp.1257-1267, March 2012 [Non-Patent Document 3] Usuki F., PNAS September 10, 2013 110 (37) 15037-15042 [Non-Patent Document 4] Usuki F., Ann Neurol. 2004 May;55(5):740-744 [Non-Patent Document 5] Gopalsamy A., Bioorganic & Medicinal Chemistry Letters, Volume 22, Issue 21, 1 November 2012, Pages 6636-6641 Summary of the Invention [Problem to be solved by the invention]

[0006] The object of the present invention is to provide a screening method for SMG1 inhibitors, a method for stabilizing SMG1 protein which is useful for a large-scale purification method of SMG1 and is used in the screening method, and a novel SMG1 inhibitor discovered by the screening method. As a result of intensive research, the inventors of the present application have found that SMG1 protein is stabilized by complexing with SMG9, and that SMG1 protein and SMG1 protein-containing protein complexes are stabilized in the presence of a polysorbate-type nonionic surfactant. Furthermore, they have found that SMG1 inhibitors can be screened by contacting the SMG1 protein complexed with SMG9 in a state stabilized in the presence of a polysorbate-type nonionic surfactant with a candidate compound for SMG1 inhibitors, measuring the kinase activity of SMG1, and selecting a compound that is found to reduce the kinase activity of SMG1. Furthermore, they have found multiple SMG1 inhibitors specific to SMG1 protein by this screening method.

[0007] That is, the present invention provides the following. (1) SMG1 protein or a protein complex containing SMG1 protein in the presence of a polysorbate-type nonionic surfactant 30 minutes or moreA method for stabilizing an SMG1 protein, comprising maintaining said protein in a nucleic acid sequence similar to that of the SMG1 protein. (2) The method described in (1), wherein the protein complex is a complex of SMG1 and SMG9. (3) The method according to (1) or (2), wherein the polysorbate-type nonionic surfactant is polyoxyethylene (20) sorbitan monolauryl ether. (4) In the presence of polysorbate-type nonionic surfactants, the SMG1 protein complexed with SMG9 was treated with a candidate compound for SMG1 inhibitors. 60 minutes to 240 minutes and measuring the kinase activity of SMG1; and A step of selecting a compound that is found to reduce the kinase activity of SMG1 A method for screening an SMG1 inhibitor, comprising: (5) The method according to (4), wherein the SMG1 protein is contacted with a library containing a plurality of candidate compounds for the SMG1 inhibitor. (6) Having any of the following structures: Compound and , contacting SMG1, SMG1 of Inhibition method .

[0008] [ka] JPEG0007591805000002.jpg3657 JPEG0007591805000003.jpg3453 Effect of the Invention

[0009] INDUSTRIAL APPLICABILITY The present invention provides a high-throughput screening method for SMG1 inhibitors, and the screening method provides SMG1 inhibitors specific to the SMG1 protein. [Brief description of the drawings]

[0010] [Figure 1]This figure shows a comparison of the activity of the conserved SMG1:SMG9 complex with that of the conserved SMG1 and conserved SMG1:SMG8SMG9 complexes used in the Examples below. [Diagram 2] FIG. 1 is a diagram illustrating the screening method for SMG1 inhibitors carried out in the Examples below. [Diagram 3] FIG. 1 is a diagram for explaining the experimental method for the enzyme stability test of a diluted SMG1 solution (1 nM) performed in the following Examples. [Figure 4] FIG. 1 shows AlphaScreen (trade name) signals obtained in the following Examples when various concentrations of Tween 20 (trade name) were added, in comparison with the results of a comparative example (Triton X-100 (trade name)) or a control (no surfactant or no ATP added). [Diagram 5] FIG. 2 is a graph showing the relationship between the concentration of Tween 20 (product name) in the first incubation and the signal / background ratio, obtained in the following Example. [Figure 6] FIG. 1 shows the relationship between the concentration of three types of SMG1 compounds and their SMG1 inhibitory activity obtained in the Examples below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] As described above, in the method for stabilizing the SMG1 protein of the present invention, the SMG1 protein or a protein complex containing the SMG1 protein is maintained in the presence of a polysorbate-type nonionic surfactant. The polysorbate-type nonionic surfactant is a fatty acid ester of sorbitol, and a preferred example of the polysorbate-type nonionic surfactant is polyoxyethylene (20) sorbitan monolauryl ether (polyoxyethylene sorbitan monolaurate (trade name: Tween 20)).

[0012] The subject of stabilization in the stabilization method of the present invention is the SMG1 protein or a protein complex containing the SMG1 protein. An example of such a complex is a complex of the SMG1 protein and the SMG9 protein. The SMG1 protein and the SMG9 protein are known proteins, and their amino acid sequences and gene sequences encoding the amino acid sequences are also known, and they can be produced by genetic engineering techniques (see Examples below). The purified SMG1 protein shows little activity, but when it is complexed with SMG9, it shows activity as a conserved SMG1:SMG9 complex.

[0013] In the stabilization method of the present invention, the SMG1 protein or a protein complex containing the SMG1 protein is maintained in a buffer containing the above-mentioned polysorbate-type nonionic surfactant. The temperature at this time is not particularly limited, but is usually 15°C to 37°C, preferably 25°C to 30°C. The concentration of the polysorbate-type nonionic surfactant is not particularly limited, but is usually about 0.01% to 1%, preferably about 0.03 to 0.1%. The concentration of the SMG1 protein or the protein complex containing the SMG1 protein is usually about 0.2 nM to 4 nM, preferably about 0.4 nM to 1.0 nM.

[0014] In the screening method for SMG1 inhibitors of the present invention, the SMG1 protein complexed with SMG9 is stabilized by the above-mentioned stabilization method, that is, in the presence of a polysorbate-type nonionic surfactant, the SMG1 protein complexed with SMG9 is contacted with a candidate compound for SMG1 inhibitors, and the kinase activity of SMG1 is measured. The contact with the candidate compound for inhibitors can be preferably carried out by contacting with a library of candidate compounds for inhibitors using AlphaScreen (trade name, manufactured by PerkinElmer), which is a commercially available kit for investigating intermolecular interactions (see Examples below). The temperature during contact is usually room temperature to 37°C. The contact time is not particularly limited, but is usually 60 minutes to 240 minutes, preferably 120 minutes to 180 minutes. The kinase activity of SMG1 can be measured by a known method. For example, when the contact is carried out using the above-mentioned AlphaScreen (trade name), it can be measured by performing fluorescence measurement using a fluorescence measuring device for AlphaScreen (trade name) (see Examples below).

[0015] The screening method of the present invention identified the following three types of compounds as SMG1 inhibitors. All of these compounds are known compounds, and their production methods are also known, but they have been newly discovered by the present invention to have inhibitory activity against SMG1.

[0016] [ka] NPD15008

[0017] [ka] NPD12823

[0018] [ka] NPD14897

[0019] As specifically shown in the Examples below, these three compounds exhibited excellent SMG1 inhibitory activity in a concentration-dependent manner.

[0020] The present invention will be specifically described below based on examples. However, the present invention is not limited to the following examples. In the examples, all "%" means mass % unless otherwise specified.

[0021] 1. Materials and Methods (I) Plasmids, enzymes, antibodies, peptides The following plasmids were constructed by cloning each cDNA fragment according to standard methods. pEFh_SBP-SMG1 (residues 2-3661 of human SMG1, codon-optimized sequence) pEFh_SMG9 (residues 1-520 of human SMG9, codon-optimized sequence) pEFh_SBP-mTOR (residues 2-2549 of rat mTOR) pEFh_HA-mLST8 (residues 2-326 of human mLST8, codon-optimized sequence used) pEFh_SBP-ATM (residues 2-3056 of human ATM) pEFh_HA-ATMIN (residues 2-823 of human ATIMN) pEFh-SBP-ATR (residues 2-2644 of human ATR) pEFh-HA-ATRIP (residues 2-791 of human ATRIP)

[0022] The anti-phosphorylated S1078 / S1096-UPF1 antibodies (clone 8E6, 7H1, 7D5, 2C9 and 9C2) were used as previously reported (2009 Genes and Development 23(9):1091-105). All of these antibodies can be used for Alpha screening. Of these antibodies, only 8E6 was compatible with culture in serum-free medium. The anti-UPF1 antibody was used as described in 2001 GenesDev15(17):2215-28. The anti-phosphorylated T37 / 46-4EBP1 (236B4) antibody was purchased from Cell Signaling Technology (catalog number 2855).

[0023] Purified enzymes were prepared as follows. The purified PIKK enzymes were purified SBP-SMG1:SMG9 complex, purified SBP-mTOR:HA-mLST8 complex, purified SBP-ATM:HA-ATMIN complex, and purified SBP-ATR:HA-ATRIP complex. Two types of plasmids expressing each protein were prepared at 6x10 8293T cells were co-transfected with polyethylenimine. Two to three days after co-transfection, the cells were lysed in NF buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.25 M sucrose, 0.5% NP-40, 1% Tween 20, 1 mM dithiothreitol [DTT], protease inhibitor cocktail (Nacalai Tesque), and phosphatase inhibitor cocktail (EDTA-free, Nacalai Tesque) containing 50 mg / ml RNase A using a homogenizer. SBP-tagged proteins were captured using Streptavidin-coated resin (GE, Streptavidin Mag-sepharose, catalog no. 28985738) by incubation at 4°C for 2 h with gentle vertical rotation and washing with NF buffer. Affinity-purified protein complexes were captured using 2 mM The proteins were eluted by incubation for 30 min at 4°C with T buffer (20 mM HEPES-KOH [pH 7.5], 150 mM NaCl, 2.5 mM MgCl2, 0.05% Tween 20) containing DTT, protease inhibitor cocktail (EDTA-free, Nacalai Tesque), phosphatase inhibitor cocktail (Nacalai Tesque), and 2 mM desthiobiotin (Sigma, catalog number D1411). The eluted proteins were dialyzed against PIKK kinase buffer (10 mM HEPES-NaOH, pH 7.5, 50 mM NaCl, 2.5 mM MgCl2). Purified DNA-PK was purchased from Promega (catalog number V5811). The following substrate peptides were synthesized by Operon Biotechnology, Inc. The underlined parts are the serine or threonine that is phosphorylated by PIKK. Biotinylated SMG1 substrate peptide (Biotin-PEG8-QIDVAL S QDSTYQG) SMG1 substrate peptide UPF1 derived (QIDVAL S QDSTYQGRRRRR) mTOR substrate peptide 4EBP1 derived (KKKKKPQDYCT T PGGTLF) ATM, ATR, DNA-PK substrate peptide p53 derived (KKKKKKSVEPPL S QETFSD)

[0024] (II) Alpha Screening The AlphaScreen (trade name) assay was performed in an OptiPlate-384 (trade name, manufactured by PerkinElmer) plate (see FIG. 2). 0.4 nM of SMG1 kinase (SBP-SMG1:SMG9 complex) was incubated with 1 μM of biotinylated SMG1 substrate peptide (Biotin-PEG8-QIDVAL SQDSTYQG [underlined is the 1096th S of UPF1 to be phosphorylated]) and 10 μM ATP dissolved in SMG1 kinase buffer (10 mM HEPES pH 7.5, 50 mM NaCl, 2.5 mM MnCl2, 0.1% Tween20 (trade name) and 0.01% bovine serum albumin (BSA)), and incubated at 26°C for 120 minutes in the presence or absence of 0.1 μL of 1 mg / mL each compound (OCDD core: 9,600 compounds, NPDepo: 20,000 compounds) in a total volume of 10 μL per well (see Figure 3). Next, EDTA diluted in AlphaScreen (trade name) detection buffer (10 mM Tris HCl pH. 7.0, 100 mM NaCl, 0.1% Tween20 (trade name) and 0.005% BSA) was added to a final concentration of 5 mM to stop the kinase reaction, and 312.5 μg / mL of anti-phosphorylated S1078 / S1096-UPF1 antibody (8E6) was added to the phosphorylated SMG1 substrate peptide and reacted for 60 minutes at 26 ° C in a total volume of 12 μL per well, and the 8E6 antibody was labeled with the phosphorylated SMG1 substrate peptide. After labeling, a mixture of streptavidin donor beads and protein A acceptor beads (final concentration: 7.5 μg / ml each) (PerkinElmer) was added to each well and incubated in a total volume of 20 μL per well at 26 ° C in the dark for 16 to 19 hours. After incubation, the plate was read at 520-620 nm with laser excitation at 680 nm using EnVision Multilabel Reader (product name, manufactured by PerkinElmer) or EnSpire Alpha (product name, manufactured by PerkinElmer), a plate reader compatible with AlphaScreen (product name).

[0025] As shown in FIG. 2, screening was performed as follows. (1) Add 0.1 μL of a 1 mg / mL stock solution of the library compound in DMSO to a 384-well assay plate. (2) Add kinase reaction mix (8 μL of 0.4 nM SMG1 (SMG1:SMG9 complex), 10 μM ATP, 1 μM biotinylated SMG1 substrate peptide in 1 x SMG1 kinase buffer, total volume 10 μL) to wells containing library compounds and to control wells not containing library compounds. Kinase reaction mix consists of: 8 μL of 0.4 nM SMG1 (SMG1:SMG9 complex), 10 μM ATP, 1 μM biotinylated SMG1 substrate peptide in 1×SMG1 kinase buffer to a total volume of 10 μL. (3) Incubate the plate at 26°C for 2 hours. (4) Add 2 μL of EDTA (final concentration 5 mM) to each well to stop the enzyme reaction, and add a solution of phosphorylated S1096 mAb in 1x detection buffer (250 ng of mAb) to bring the total volume to 12 μL. (5) Incubate the plate at 26°C for 1 hour. (6) Add 8 μL of a suspension of acceptor beads and donor beads in 1x detection buffer (final concentration of each bead is 7.5 μg / mL) to each well to make the total volume 20 μL. (7) Incubate the plate at 23°C for 16 to 19 hours. (8) Detect the Alpha signal using an EnVision Multilabel Reader (trade name) or EnSpire Alpha (trade name).

[0026] 2. Results (I) Stabilization Because the AlphaScreen process requires time for multiple plate injections, SMG1 kinase should be incubated at room temperature for at least 30 minutes before the kinase reaction. However, SMG1 kinase activity was reduced to one-fourth by incubation at 26°C for 30 minutes before the kinase reaction (Figure 4, "0"). To suppress this reduction in activity, the effects of additives such as surfactants were examined. Some of the results are shown in Figure 4. 0.096% TritonX-100 further reduced SMG1 kinase activity. On the other hand, the addition of 0.0096-0.86% Tween20 improved SMG1 kinase activity, and no reduction in activity was detected by incubation at 26°C for 30 minutes. This demonstrated that the SMG1-SMG9 complex was stabilized by Tween20. The relationship between the concentration of Tween 20 (trade name) during the first incubation and the signal / background (S / B) ratio is shown in FIG. 5 for the cases where the first incubation was performed and where it was not performed.

[0027] (II) Identified SMG1 inhibitors By the above method, the above-mentioned three compounds, namely, NPD15008, NPD12823 and NPD14897, were screened as SMG1 inhibitors from the 9600 compounds contained in the library.

[0028] The relationship between the logarithm of the concentration (M) of the three compounds and the SMG1 inhibitory activity is shown in Figure 6. The IC50 values ​​calculated from the above are also shown in Figure 6. These results confirmed the SMG1 inhibitory activity of these three compounds.

[0029] Furthermore, the inhibitory activity of the three compounds obtained against various kinases (SMG1, DNA-PK, ATR, mTOR, ATM) was examined at ATP concentrations of 10 μM or 1 μM. Specifically, this was performed as follows. SQDSTYQGRRRRR (underlined is Ser 1096 of UPF1), mTOR: KKKKKPQDYCT T PGGTLF (underlined: Thr 37 of 4EBP1), ATM, ATR, DNA-PK: KKKKKSVEPPL S QETFSD (underlined part is Ser 15 of p53) was incubated with 16.6 nM to 49.8 nM of radiolabeled ATP (γ 32 P-ATP), 1 μM or 10 μM ATP in kinase buffer (10 mM HEPES pH 7.5, 50 mM NaCl, 2.5 mM MnCl2, 0.1% Tween20 (trade name) and 0.01% BSA) and 0 μM to 50 μM of each compound were mixed and incubated at 30°C for 15 minutes. After the reaction, the kinase reaction was terminated by heat inactivation at 65°C for 15 minutes. After heat inactivation, the reaction solution was spotted on the center of a 1 cm square P81 phosphocellulose filter paper (Millipore). Immediately after spotting, the filter paper was placed in a 75 mM phosphoric acid solution and slowly shaken for 5 minutes. The filter paper was then transferred to a new 75 mM phosphoric acid solution and slowly shaken for 5 minutes in the same manner. This washing procedure was repeated three times. After the final wash in phosphoric acid, the filter paper was transferred to a 1.5 mL microcentrifuge tube and " 32 The Cerenkov count was measured using a liquid scintillation counter in the absence of scintillation fluid, using the "P program".

[0030] The results are shown in Table 1 below. The above three compounds specifically inhibited only SMG1 activity. In contrast, the SMG1 inhibitor (Pfizer 11j) described in Non-Patent Document 5 also inhibited mTOR activity, and the inhibitory activity was not specific to SMG1.

[0031] [Table 1]

Claims

1. A method for stabilizing SMG1 protein, comprising maintaining SMG1 protein or a protein complex containing SMG1 protein in the presence of a polysorbate-type nonionic surfactant for 30 minutes or more.

2. The method of claim 1 , wherein the protein complex is a complex of SMG1 and SMG9.

3. 3. The method according to claim 1 or 2, wherein the polysorbate-type nonionic surfactant is polyoxyethylene (20) sorbitan monolauryl ether.

4. A step of contacting the SMG1 protein complexed with SMG9 with a candidate compound for an SMG1 inhibitor for 60 to 240 minutes in the presence of a polysorbate-type nonionic surfactant, and measuring the kinase activity of SMG1; A step of selecting a compound that is found to reduce the kinase activity of SMG1 A method for screening an SMG-1 inhibitor, comprising:

5. The method of claim 4 , wherein the SMG1 protein is contacted with a library containing a plurality of candidate SMG1 inhibitor compounds.

6. A method for inhibiting SMG1, comprising contacting SMG1 with a compound having any of the structures below: [Formula 1] [ka] [ka]

Citation Information

Patent Citations

  • immunostimulants

    JP2019073466A

  • 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as MTOR, PI3, and HSMG-1 kinase inhibitors, and their syntheses

    WO2010120991A1

  • Polysorbate quantification assay

    WO2019002295A1